2
Dec
2021

The Variant on the Move

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Moderna’s Home Run, Amylyx Bounces Back, & Enveda Advances Workout-in-a-Pill
Jazz Scoops Up Epilepsy Drug, Boulevard Aims for Immune Reset, & AbCellera Matures
Takeda Wins First-in-Class Orexin OK, Lilly’s Obesity Money Gusher, & Three New IPOs
J&J Buys In Vivo CAR-T, Sarepta’s New Boss, & Three IPOs in the Queue